Immunic holds RMS R&D Day webinar; presentation details not in filing

IMMUNIC, INC.

Immunic hosted RMS R&D Day webinar Sept 9, 2026, 11:00-12:30 ET via video conference.
Presentation content not included in filing text; no specific clinical data or milestones disclosed in body.
Forward-looking statements cite vidofludimus calcium and potential confirmatory phase 3 trial in progressive MS.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.